Logo
x

Search

Subscribe Now

Oculis

Oculis Reports the Completion of Patient Enrolment in P-III Trial (OPTIMIZE) of OCS-01 for the Treatment of Inflammation and Pain

Oculis Reports the Completion of Patient Enrolment in P-III Trial (OPTIMIZE) of OCS-01 for the Treatment of Inflammation and Pain

  • March 17, 2023
Oculis to go Public via EBAC SPAC Merger for ~$220M

Oculis to go Public via EBAC SPAC Merger for ~$220M

  • October 19, 2022
Oculis Reports Results of OCS-01 in P-II (DX-211) Study for the Treatment of Diabetic Macular Edema

Oculis Reports Results of OCS-01 in P-II (DX-211) Study for the Treatment of Diabetic Macular Edema

  • September 6, 2022
Oculis Published P-II Study Results of Licaminlimab (OCS-02) for the Treatment of Severe Dry Eye Disease in Clinical Ophthalmology

Oculis Published P-II Study Results of Licaminlimab (OCS-02) for the Treatment of Severe Dry Eye Disease in Clinical Ophthalmology

  • August 24, 2022
Oculis Reports the First Patient Enrollment of OCS-01 in P-III (OPTIMIZE) Trial for the Treatment of Inflammation and Pain Following Cataract Surgery

Oculis Reports the First Patient Enrollment of OCS-01 in P-III (OPTIMIZE) Trial for the Treatment of Inflammation and Pain Followi...

  • June 29, 2022
Oculis Entered into a License Agreement with Accure Therapeutics to Develop and Commercialize ACT-01 for Acute Optic Neuritis and Glaucoma

Oculis Entered into a License Agreement with Accure Therapeutics to Develop and Commercialize ACT-01 for Acute Optic Neuritis and...

  • March 3, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.